Capital Research Global Investors’s Structure Therapeutics GPCR Stock Holding History

Capital Research Global Investors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,164,145	Closed	-$37.5M	–	445
2025 Q1	$37.5M	Sell	2,164,145 -1,373,196	-39%	-$33.6M	0.01%	372
2024 Q4	$95.9M	Buy	3,537,341 +6,891	+0.2%	+$244K	0.02%	306
2024 Q3	$155M	Buy	3,530,450 +399,140	+13%	+$15.4M	0.03%	243
2024 Q2	$123M	Buy	3,131,310 +1,603,827	+105%	+$65.9M	0.03%	259
2024 Q1	$65.5M	Buy	1,527,483 +553,948	+57%	+$23.4M	0.01%	320
2023 Q4	$39.7M	Buy	973,535 +628,687	+182%	+$36M	0.01%	341
2023 Q3	$17.3M	Buy	+344,848	New	+$11.1M	﹤0.01%	369

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Research Global Investors's GPCR Position: Q2 2025 in Review

Capital Research Global Investors sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 2,164,145 shares — an estimated $37.5M sold.

Capital Research Global Investors first reported a position in GPCR in Q3 2023 and held it in 7 quarters. The position peaked at $155M in Q3 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

Capital Research Global Investors reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
Capital Research Global Investors sold 2,164,145 Structure Therapeutics shares in Q2 2025, an estimated $37.5M.
Capital Research Global Investors first reported a position in Structure Therapeutics in Q3 2023 and held it in 7 quarters.
Capital Research Global Investors's Structure Therapeutics position peaked at $155M in Q3 2024.
172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on Capital Research Global Investors's 13F filing for Q2 2025, filed 13 Aug 2025.